NCT05008276 Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
| NCT ID | NCT05008276 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Petter Bjornstad |
| Condition | Type 2 Diabetes Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-09-27 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2021-09-27 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.
Eligibility Criteria
Inclusion Criteria: * HbA1c ≥6.0% for untreated high-risk group * BMI ≥ 85th %ile for high-risk group * Normal HbA1c ≤5.6% for control group * Type 1 diabetes (T1D) Antibody negative Exclusion Criteria: * History of Chronic kidney disease (CKD) or acute kidney injury (AKI) * Metabolic disorder prohibiting safe fasting * Iodine or penicillin allergy * Pregnancy * Thrombophilia * MRI contraindications * Hormone therapy
Contact & Investigator
Petter Bjornstad, MD
PRINCIPAL INVESTIGATOR
University of Washington - Medicine Diabetes Institute
Frequently Asked Questions
Who can join the NCT05008276 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 14 Years, studying Type 2 Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05008276 currently recruiting?
Yes, NCT05008276 is actively recruiting participants. Contact the research team at pettermb@uw.edu for enrollment information.
Where is the NCT05008276 trial being conducted?
This trial is being conducted at Aurora, United States, Seattle, United States.
Who is sponsoring the NCT05008276 clinical trial?
NCT05008276 is sponsored by Petter Bjornstad. The principal investigator is Petter Bjornstad, MD at University of Washington - Medicine Diabetes Institute. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.